<DOC>
	<DOCNO>NCT00041301</DOCNO>
	<brief_summary>RATIONALE : Quality life assessment patient undergoing prostate cancer treatment may help determine intermediate long-term effect treatment patient . PURPOSE : Clinical trial study effectiveness two questionnaire assess quality life patient prostate cancer .</brief_summary>
	<brief_title>Assessing Quality Life Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Assess scale structure , psychometric validity , reliability quality life measurement use EORTC QLQ-C30 prostate cancer-specific QLQ-PR25 questionnaire patient stage I-IV prostate cancer . OUTLINE : This multicenter study . Patients stratify accord stage disease ( local locally advanced disease v metastatic disease ) . Patients complete EORTC QLQ-C30 prostate cancer-specific QLQ-PR25 questionnaire therapy 3 month start therapy . Patients stratum II also complete questionnaire 6 month start therapy . PROJECTED ACCRUAL : A total 375 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm prostate cancer Stratum I : Clinically localize primary prostate cancer T1T3 , G1G3 , N0 , M0 Plan undergo radical prostatectomy OR Local locally advance primary prostate cancer T1T4 , G1G3 , N0 , M0 Plan undergo radiotherapy curative intent Stratum II : Metastatic prostate cancer T1T4 , G1G3 , N1 , M0M1 OR T1T4 , G1G3 , N01 , M1 Plan receive hormonal treatment No antiandrogen monotherapy No cerebral metastasis PATIENT CHARACTERISTICS : Age : Any age Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : Mentally fit complete questionnaire Literate language questionnaires No psychological , familial , sociological , geographical condition would preclude compliance No concurrent malignancy except basal cell skin cancer No concurrent participation quality life investigation would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : See Disease Characteristics No prior neoadjuvant hormonal treatment Planned adjuvant hormonal therapy ( orchiectomy , luteinizing hormonereleasing hormone analogue , maximal androgen blockade ) allow patient stratum I Radiotherapy : See Disease Characteristics No interstitial radiotherapy More 2 year since prior radiotherapy ( stratum II ) Surgery : See Disease Characteristics More 2 year since prior prostatectomy ( stratum II ) Other : No prior treatment prostate carcinoma</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>